These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6331828)

  • 1. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease.
    Bannon MJ; Goedert M; Williams B
    Biochem Pharmacol; 1984 Sep; 33(17):2697-8. PubMed ID: 6331828
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms underlying neuronal degeneration in Parkinson's disease: an experimental and theoretical treatise.
    Langston JW
    Mov Disord; 1989; 4 Suppl 1():S15-25. PubMed ID: 2542782
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuromelanin and its possible protective and destructive properties.
    Lindquist NG; Larsson BS; Lydén-Sokolowski A
    Pigment Cell Res; 1987; 1(3):133-6. PubMed ID: 3334086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of new pharmacological approaches in Parkinson's disease.
    Carlsson A
    Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631
    [No Abstract]   [Full Text] [Related]  

  • 5. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopamine D2 receptor hypersensitivity in the mouse is transient.
    Peroutka SJ; DeLanney L; Irwin I; Ison PJ; Ricaurte G; Schlegel JR; Langston JW
    Res Commun Chem Pathol Pharmacol; 1985 May; 48(2):163-71. PubMed ID: 3875136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease: current view.
    Langston JW
    Am Fam Physician; 1987 Mar; 35(3):201-6. PubMed ID: 3103408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cocaine blocks the dopamine depletion induced by MPTP.
    Mayer RA; Jarvis MF; Wagner GC
    Res Commun Chem Pathol Pharmacol; 1985 Jul; 49(1):145-8. PubMed ID: 3875884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
    Kito S; Miyoshi R; Mizuno K; Nitta K; Matsubayashi H; Yamamura Y; Tahara E
    Adv Neurol; 1987; 45():159-65. PubMed ID: 2881441
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinson's disease in 1984: an update.
    Lang AE; Blair RD
    Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pethidine and parkinsonism. 1-Metyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a new neurotoxin].
    Hunskår S
    Tidsskr Nor Laegeforen; 1986 Jan; 106(3):219-20. PubMed ID: 3485316
    [No Abstract]   [Full Text] [Related]  

  • 13. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985.
    J Neural Transm Suppl; 1986; 20():1-81. PubMed ID: 3489069
    [No Abstract]   [Full Text] [Related]  

  • 14. Tissue culture model for studying MPTP toxicity to dopamine neurons.
    Mytilineou C; Cohen G
    Adv Neurol; 1987; 45():145-8. PubMed ID: 3493622
    [No Abstract]   [Full Text] [Related]  

  • 15. MPTP: insights into the etiology of Parkinson's disease.
    Langston JW
    Eur Neurol; 1987; 26 Suppl 1():2-10. PubMed ID: 3556187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of MAO in MPTP toxicity--a review.
    Glover V; Gibb C; Sandler M
    J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of evidence supporting a role for dopamine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
    Schmidt CJ; Bruckwick E; Lovenberg W
    Eur J Pharmacol; 1985 Jul; 113(1):149-50. PubMed ID: 2864262
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease, vitamin E, and mitochondrial energy metabolism.
    Hornsby PJ
    Arch Neurol; 1989 Aug; 46(8):840-1. PubMed ID: 2787979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.